Home Cart Sign in  
Chemical Structure| 168079-32-1 Chemical Structure| 168079-32-1

Structure of Lixivaptan
CAS No.: 168079-32-1

Chemical Structure| 168079-32-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lixivaptan is an orally active and selective vasopressin receptor V2 antagonist with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.

Synonyms: WAY-VPA 985; VPA-985; CRTX 080

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lixivaptan

CAS No. :168079-32-1
Formula : C27H21ClFN3O2
M.W : 473.93
SMILES Code : O=C(NC1=CC=C(C(N2CC3=CC=CN3CC4=CC=CC=C24)=O)C(Cl)=C1)C5=CC(F)=CC=C5C
Synonyms :
WAY-VPA 985; VPA-985; CRTX 080
MDL No. :MFCD00937905
InChI Key :PPHTXRNHTVLQED-UHFFFAOYSA-N
Pubchem ID :172997

Safety of Lixivaptan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Lixivaptan

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01056848 - Completed - United States, California ... More >> Torrance Clinical Research Lomita, California, United States, 90717 United States, Florida Innovative Research of West Florida Clearewater, Florida, United States, 33756 Fleming Island Center for Clinical Research Fleming Island, Florida, United States, 32003 Jacksonville Center for Clinical Research Jacksonville, Florida, United States, 32216 United States, Missouri Millenium Psychiatric Associates, LLC Creve Cour, Missouri, United States, 63141 United States, Nebraska Internal Medical Associates of Grand Island, PC Grand Island, Nebraska, United States, 68803 Less <<
NCT00578695 Hyponatremia Phase 3 Completed - -
NCT00660959 Hyponatremia With Normal Extra... More >>cellular Fluid Volume Less << Phase 3 Completed - -
NCT00876798 Euvolemic Hyponatremia Phase 3 Completed - -
NCT00675701 Healthy Phase 1 Completed - United States, Texas ... More >> Research Site 1 Austin, Texas, United States, 78744 Less <<
NCT00876876 Hypervolemic Hyponatremia PHASE3 WITHDRAWN 2025-12-10 -
NCT03717181 Polycystic Kidney NO_LONGER_AVAILABLE - Mayo Clinic, Rochester, Minnes... More >>ota, 55905, United States Less <<
NCT03487913 Autosomal Dominant Polycystic ... More >>Kidney Disease Less << PHASE2 COMPLETED 2020-02-11 Palladio Biosciences Clinical ... More >>Site, Los Angeles, California, 90022, United States|Palladio Biosciences Clinical Site, Jacksonville, Florida, 32216, United States|Palladio Biosciences Clinical Site, Miami, Florida, 33155, United States|Palladio Biosciences Clinical Site, Miami, Florida, 33165, United States|Palladio Biosciences Clinical Site, Palmetto Bay, Florida, 33157, United States|Palladio Biosciences Clinical Site, Tampa, Florida, 33612, United States|Palladio Biosciences Clinical Site, Baltimore, Maryland, 21201, United States|Palladio Biosciences Clinical Site, Rochester, Minnesota, 55902, United States|Palladio Biosciences Clinical Site, Kansas City, Missouri, 64111, United States|Palladio Biosciences Clinical Site, Laurelton, New York, 11413, United States|Palladio Biosciences Clinical Site, Indiana, Pennsylvania, 15701, United States|Palladio Biosciences Clinical Site, Nashville, Tennessee, 66160, United States|Palladio Biosciences Clinical Site, Salt Lake City, Utah, 84115, United States Less <<
NCT01055912 Congestive Heart Failure Phase 2 Completed - -
NCT04152837 Polycystic Kidney Disease, Adu... More >>lt|ADPKD Less << PHASE3 TERMINATED 2022-07-29 University of California Los A... More >>ngeles, Los Angeles, California, 90025, United States|University of Chicago Medicine & Biological Sciences, Chicago, Illinois, 60637, United States|Mayo Clinic, Rochester, Minnesota, 55905, United States|Brookview Hills Research Associates, LLC, Winston-Salem, North Carolina, 27103, United States|Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, 18107, United States|Nephrology Associates of Northern Virginia, Inc., Fairfax, Virginia, 22033, United States Less <<
NCT05208866 Polycystic Kidney Disease, Adu... More >>lt Less << PHASE3 TERMINATED 2022-07-29 Northeast Clinical Research Ce... More >>nter, LLC, Bethlehem, Pennsylvania, 18107, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.55mL

2.11mL

1.06mL

21.10mL

4.22mL

2.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories